GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2008

FAB Awarded SBIR Grant to Advance Cell-Free Protein Synthesis Platform

  • Fundamental Applied Biology (FAB) received $500,000 for the development of its cell-free protein synthesis technology toward commercialization. This SBIR phase IIB grant comes from the NSF.

    During the STTR phase I and phase II NSF projects, FAB reported that certain proteins could be made in a soluble form through a cell-free system that was controllable and efficient. With the current award, FAB will continue to develop the technology with a market-driven, therapeutic protein as FAB’s first target product.

    “The grant will allow FAB to further develop and optimize our cell-free technology to enable the production of pharmaceutical protein therapeutics with the goal of improving their biological activity,” says Daniel S. Gold, Ph.D., CEO.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?